

Product Name: AG-1478 Revision Date: 01/10/2021

# **Product Data Sheet**

## **AG-1478**

**Cat. No.:** A8357

**CAS No.:** 153436-53-4 **Formula:** C16H14CIN3O2

**M.Wt:** 315.75

**Synonyms:** Tyrphostin AG-1478; AG 1478; NSC 693255;

AG1478

Target: JAK/STAT Signaling

Pathway: EGFR

In Vitro

Storage: Store at -20°C

# Solvent & Solubility

insoluble in H2O; ≥15.8 mg/mL in DMSO; ≥2.38 mg/mL in EtOH with gentle warming

Mass Solvent 1mg 5mg 10mg Preparing Concentration Stock Solutions 15.8353 mL 31.6706 mL 1 mM 3.1671 mL 5 mM 3.1671 mL 0.6334 mL 6.3341 mL 10 mM 0.3167 mL 1.5835 mL 3.1671 mL

Please refer to the solubility information to select the appropriate solvent.

## **Biological Activity**

Shortsummary	EGFR inhibitor,potent and selective	
IC <sub>50</sub> & Target	3 nM (EGFR), >100 μM (HER2), >100 μM (PDGFR)	
In Vitro	Cell Viability Assay	9899
	Cell Line:	Human hepatocellular carcinoma HA22T/VGH cell line
	Preparation method:	Soluble in DMSO > 15.8mg/mL. General tips for obtaining a higher
		concentration: Please warm the tube at 37°C for 10 minutes and/or shake it in
		the ultrasonic bath for a while. Stock solution can be stored below -20°C for
		several months.

	Reacting conditions:	6.25, 12.5, 25µM; 24hr
	Applications:	Tyrphostin AG-1478, a potent and specific inhibitor of EGFR (Epidermal
		Growth Factor Receptor) tyrosine kinase, plays a key role in the control of
		normal cellular growth and abnormal cell proliferation. Tyrphostin AG-1478
		shows an enhanced in vitro anti-tumor activity in HA22T/VGH cells when
	610	entrapmented into NLC(nanostructured lipid carriers) systems compared to
		free drug.
In Vivo	Animal experiment	
	Animal models:	Male C57BL/6 mice aged 8 weeks, male ApoE-/- mice aged 8 weeks
	Dosage form:	10 mg/kg/day, 8 weeks, oral gavage
	Applications:	Administration of AG1478 significantly reduced myocardial inflammation,
		fibrosis, apoptosis, and dysfunction in both two obese mouse models.
	Other notes:	Please test the solubility of all compounds indoor, and the actual solubility may
		slightly differ with the theoretical value. This is caused by an experimental
	310	system error and it is normal.

## **Product Citations**

See more customer validations on www.apexbt.com.

### References

- [1]. Bondì ML1, Azzolina A, et al, Entrapment of an EGFR inhibitor into nanostructured lipid carriers (NLC) improves its antitumor activity against human hepatocarcinoma cells. J Nanobiotechnology, 2014. 12(21): p. 1477-3155.
- [2]. Li W1,2, Fang Q1, EGFR Inhibition Blocks Palmitic Acid-induced inflammation in cardiomyocytes and Prevents Hyperlipidemia-induced Cardiac Injury in Mice. Sci Rep. 2016 Apr 18;6:24580. doi: 10.1038/srep24580.

## Caution

#### FOR RESEARCH PURPOSES ONLY.

#### NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

Specific storage and handling information for each product is indicated on the product datasheet. Most APExBIO products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Shortterm storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage. We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.

## **APExBIO Technology**

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054. Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com



APE, BIO

APE BIO

APE BIO

APE BIO

APE, BIO

APEVEIO